A First-in-Human Study to Evaluate the Safety and Tolerability of ALN-APP in Patients with EOAD
Phase 1
- Conditions
- Early-onset Alzheimer's disease (EOAD)MedDRA version: 24.1Level: LLTClassification code: 10086384Term: Early onset Alzheimer´s disease Class: 100000004848Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
- Registration Number
- CTIS2023-508363-79-00
- Lead Sponsor
- Alnylam Pharmaceuticals Inc.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 59
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method